Patents Examined by Samira J Jean-Louis
  • Patent number: 11365189
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: June 21, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: John Heymach, Jacqulyne Robichaux, Monique Nilsson, Philip Jones, Jason Cross, Jay Theroff
  • Patent number: 11358948
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: June 14, 2022
    Assignee: KYMERA THERAPEUTICS, INC.
    Inventors: Nello Mainolfi, Nan Ji, Yi Zhang, Matthew M. Weiss
  • Patent number: 11352360
    Abstract: Disclosed are imidazole and thiazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, A, Z, R1 and R? are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-?, and can be used to treat disease by blocking TGF-? signaling.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: June 7, 2022
    Assignees: Rigel Pharmaceuticals, hic., Bristol-Myers Squibb Company
    Inventors: Todd Kinsella, Marina Gelman, Hui Hong, Ihab S. Darwish, Rajinder Singh, Jiaxin Yu, Robert M. Borzilleri, Upender Velaparthi, Peiying Liu, Chetan Padmakar Dame, Hasibur Rahaman, Jayakumar Sankara Warrier
  • Patent number: 11351155
    Abstract: A method of treating disorders associated with NO/SNO deficiency or benefiting from increased SNO in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, SNO-CoAR inhibitor, and/or SNO-CoA at an amount(s) effective to promote S-nitrosylation of proteins in the subject.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: June 7, 2022
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Jonathan Stamler
  • Patent number: 11352369
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: June 7, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Patent number: 11345691
    Abstract: The present invention relates to prodrug compounds and their use in the treatment of Cystic Fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: May 31, 2022
    Assignees: AbbVie Global Enterprises Ltd., Galapagos NV
    Inventors: Didier Philippe Robert Schils, Sam Bob Corveleyn, Herman Augustinus De Kock, Matthew Beau Dufek
  • Patent number: 11337937
    Abstract: The present invention discloses compositions, methods, and systems of treating female sexual dysfunction by stimulating the contraction of the smooth muscle of the nipple. The smooth muscle in the nipple expresses trace amine associated receptors and thus can be contracted through a class of trace amine associated receptor agonists such as octopamine or tyramine, but any agent that promotes contraction of smooth muscle can be considered for the methods and compositions described herein. The contraction of the smooth muscle erects the nipple and increases female sexual arousal. The smooth muscle stimulatory compound can be formulated in a solution, foam, ointment, gel, spray, lotion, powder, topical cream, emulsion, slow release capsule or any similar method, compound, or delivery vehicle including a pre-wetted gauze or cotton pad. Additionally, the disclosed composition can be used to improve the quality of a sexual experience, e.g.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: May 24, 2022
    Inventors: Ofer A. Goren, John McCoy
  • Patent number: 11325911
    Abstract: The present invention relates to a method for preparing 3-[(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[1,2-a] [1,4]benzodiazepin-4-yl]-propionic acid methyl ester starting from 3-[(3S)-7-bromo-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-[1,4]-benzodiazepin-3-yl] propionic acid methyl ester, and novel compounds useful as intermediates in said method, i.e., (3S)-3-[7-bromo-2-(2,2-dimethoxypropylamino)-5-pyridin-2-yl-3H-benzo[e] [1,4]diazepin-3-yl]propionic acid methyl ester.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: May 10, 2022
    Inventors: Carles Sánchez Casals, Alicia Dobarro Rodríguez
  • Patent number: 11319315
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 3, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Li, Tianan Fang, James R. Corte, Jun Shi, Hao Zhang, Lawrence J. Kennedy, Shiwei Tao
  • Patent number: 11319309
    Abstract: The present invention provides compounds of Formula (Ia) or (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 3, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Ying Wang, Peter Tai Wah Cheng
  • Patent number: 11311498
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: April 26, 2022
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11312706
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: April 26, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Ying Wang, Peter Tai Wah Cheng, Jun Li, Steven J. Walker
  • Patent number: 11292786
    Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: April 5, 2022
    Assignee: Hanmi Pharm. Co., Ltd.
    Inventors: In Hwan Bae, Ji Sook Kim, Jae Yul Choi, Seok Jong Kang, Young Gil Ahn, Kwee Hyun Suh
  • Patent number: 11286247
    Abstract: The invention relates to a series of novel compounds containing acryloyl group. In particular, the invention relates to acryloyl group-containing compounds shown in formula (1) and the preparation method thereof, and application of the compounds shown in formula (1) and pharmaceutically acceptable salts thereof in preparation of medicaments for treating, regulating and/or preventing diseases related to physiological conditions related to CRM1 protein.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: March 29, 2022
    Assignee: WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD.
    Inventors: Houxing Fan, Yuli Xie
  • Patent number: 11278556
    Abstract: The invention generally relates to methods to prevent and/or inhibit viral infection as well as to inhibit inflammation and/or pathogen infection by administering at least one xylitol lipid analog or compositions comprising at least one xylitol lipid analog to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one xylitol lipid analog or compositions comprising at least one xylitol lipid analog to an individual.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: March 22, 2022
    Assignee: National Jewish Health
    Inventor: Dennis R. Voelker
  • Patent number: 11279687
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An embodiment of the invention is the provision of a compound of Formula IIIA.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: March 22, 2022
    Assignees: Valo Health, Inc., Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng, Po-Wai Yuen
  • Patent number: 11266654
    Abstract: The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: March 8, 2022
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Sophia Gayle, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad, Matt Dyer, Tian Xu
  • Patent number: 11254660
    Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: February 22, 2022
    Assignee: Pfizer Inc.
    Inventors: William Paul Esler, Trenton Thomas Ross
  • Patent number: 11246929
    Abstract: Combination therapy for the treatment of cancer.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: February 15, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Lars Damstrup, Thomas Grombacher, Christian Sirrenberg, Lyubomir Vassilev, Astrid Zimmermann
  • Patent number: 11236065
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: February 1, 2022
    Assignee: Edgewise Therapecutics, Inc.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele, Grace Uzoho